Elanco Animal Health has agreed to sell its aqua business to Merck Animal Health for $1.3 billion (€1.2B) in cash, 7.4 times the businesses’ estimated revenue in 2023.
This strategic move allows Elanco to refocus on pet health and livestock sustainability and accelerate its debt payment.
The Indiana-based company will explore untapped and emerging spaces like monoclonal antibodies for the pet market.
Elanco’s aqua business portfolio brought in an estimated revenue of $175 million (€162M) in 2023.
Merck builds on its aqua portfolio
According to the deal, Meck Animal Health will absorb old water and warm water aqua products, including vaccines, antiparasitic treatments, water supplements and nutrition, to further its goal of being the leading aqua health business.
“We believe this acquisition, coupled with our commercial and scientific prowess, will deliver enhanced benefits for our aqua customers,” comments Rick DeLuca, President of Merck Animal Health.
The latest articles
Digital boosts revenue of Petz in Q1 2024
The Brazilian pet retailer posted an online gross revenue increase of 16.6% vs. a drop of 6.1% in its physical stores.
Russia’s pet population has risen 11% since 2020
New data reveals that last year, more than half of households in the country owned a pet. GlobalPETS dives into the insights.
The American Kennel Club acquires grooming certification program
The Professional Grooming Credential is a voluntary scheme to validate pet groomers’ knowledge and technical skills.
Weekly newsletter to stay up-to-date
Discover what’s happening in the pet industry. Get the must-read stories and insights in your inbox.